NCT03174977View on ClinicalTrials.gov

Pharmacokinetics Distribution of Raltegravir by PET/MR

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2018

Primary Completion Date

November 1, 2024

Study Completion Date

January 1, 2025

Conditions
HIV-1-infection
Interventions
DRUG

18F-Raltegravir

A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.

Trial Locations (1)

94110

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER